MUMBAI, INDIA, Aug 23, 2024 - (ACN Newswire via SeaPRwire.com) - InfoComm India, India’s foremost professional audiovisual (Pro AV) exhibition, is set to return to Mumbai from 3-5 September 2024 at the Jio World Convention Centre (JWCC). This year, InfoComm India 2024 expands beyond Pavilions 1 to 3 at JWCC, incorporating Jasmine Hall (at Level 3) for an even larger showcase of innovative solutions. It will showcase over 250 brands from more than 10 countries, including 35 first-time exhibitors. Registration is now open for professionals and businesses looking to deepen their Pro AV expertise.InfoComm India 2024, 3-5 September 2024, Jio World Convention Center, Mumbai | Attend over 48 free summit sessions, across 14 tracks, featuring insights from more than 50 industry leaders.Visitors can discover a plethora of solutions ranging from the latest in digital signage, to intelligent video conference systems, from artificial intelligence (AI) in LED virtual production to naked eye 3D displays, smart classroom solutions, interactive immersive projection mapping and more catering to a wide range of sectors such as education, finance, live events, urban development & smart cities. The exhibition will showcase top-tier products and innovations from renowned global brands and emerging industry players, including AERO, BENQ, Crestron, Harman, QSYS, Barco, AET, Samsung, and PeopleLink, along with WACOM, DVSI, Neotouch, Yotech Infocom, Onfinity Technologies and 30 more who are exhibiting for the first time at InfoComm India.With an expanded show floor space at Jasmine Hall, visitors can look forward to even more innovators in the Pro AV and technology space including TOYO, 4 Squares Corporation, Altex, Black Box and Wah Lee to name a few. AVIXA will also be making its presence felt at Jasmine Hall with interactive and knowledge-packed seminars hosted at its booth throughout the three days.InfoComm India 2024 expands beyond Pavilions 1 to 3 at JWCC, incorporating Jasmine Hall (at Level 3) for an even larger showcase of innovative solutions.The 2024 InfoComm India Summit will offer over 48 free-to-attend seminars across 14 specialized tracks led by over 50 industry leaders as speakers. A glimpse of the exciting lineup of sessions includes a kick-off overview “Navigating New Horizons: Insights and Innovations Shaping India’s Pro AV Landscape” led by David Labuskes, CTS, CAE, RCDD, Executive Director and CEO, AVIXA , ‘Live Events & Experiential Planning’ exploring Pro AV application for live events, as well as industry-focused sessions dedicated to smart cities, hospitality, and education sectors like "Future of Learning Spaces", “Securing the Future: Cybersecurity Strategies, Economics, and Risk Management”, Digital Signage in the AI-age which explores real-world strategies using AI, VR, and digital platforms for immersive experiences."India's digital transformation is truly inspiring," said June Ko, Executive Director of InfoComm India. "We see a vibrant energy and a thirst for innovation across the country. InfoComm India 2024 is our way of bringing together the brilliant minds and passionate hearts that are shaping this new era of technology in India. We envision InfoComm India as the premier destination for the Pro AV community to exchange ideas, foster partnerships, and collectively drive the industry forward.”Connection is at the heart of InfoComm India 2024. A host of networking opportunities are designed to connect attendees with industry experts, thought leaders, and peers. They include the Breakfast Networking Hour at Luminary Lounge (Jasmine Hall) on 2 and 3 September, 9.30am to 10.00am; Flashtrack seminars and networking events at AVIXA booth; daily New Technology and Products Show Floor Tours and more.InfoComm India 2024 will showcase over 250 brands, with 35 first-time exhibitors.For full details on exhibitors, products, summit agenda, registration, and sponsorship opportunities, visit www.infocomm-india.comTo access more press information of InfoComm India 2024, please visit: Digital Press Office KitFor more information, please contact:Rest of the WorldAngieEngMarketing DirectorInfoCommAsiaPteLtdangieeng@infocommasia.comIndiaSooraj DhawanDirectorFalcon Exhibitions Pvt. Ltd.sooraj@falconfirst.com Copyright 2024 ACN Newswire via SeaPRwire.com.
Web3 with Tobi & Brent to Host Exclusive Networking Event and AfterParty During Token2049 Singapore
Summary: Coinciding with F1 week and TOKEN2049 at the iconic Marina Bay Sands in Singapore, this edition of the global event series “Web3 with Tobi & Brent” will serve as a hub for the Web3 community, facilitating connections and idea exchanges among industry leaders and developers.The event will feature a headline set by renowned DJ Dillon Francis, with artists Jade Rasif, Nicole Chen, and CeVie joining the lineup to offer unparalleled entertainment alongside networking opportunities at the iconic MARQUEE Nightclub. Co-hosted by prominent Web3 entities such as 280 Capital, Biptap, Cytonic, BitcoinOS and TBV, and supported by key partners like Limewire, Altcoin Daily, ZkPass, Ripple, 10X Capital, yourPRstrategist (YPRS), XDC Plug and Play, FOMO Ventures, ShibaDino, KINO, LBank, and Bitrue, the event will attract significant industry figures and offer unique insights into the Web3 ecosystem.SINGAPORE, Aug 23, 2024 - (ACN Newswire via SeaPRwire.com) - "Web3 with Tobi & Brent," a premier event series in the Web3 community, is set to host a renowned networking event and afterparty on September 17, 2024, at MARQUEE, Marina Bay Sands, Singapore. Coinciding with the TOKEN2049 conference, the event is strategically delivering high-value networking with the signature “Web3 with Tobi & Brent” party experience. Entrepreneurs, investors, developers and industry KOLs are set to come together for a night to be remembered.The event begins at 9PM with a networking session, followed by an afterparty at the MARQUEE Nightclub from 10:00 PM until late. Following a lineup of incredible artists including CeVie, Jade Rasif and Nicole Chen, guests can look forward to a headlining performance by the internationally acclaimed DJ, Dillon Francis. Known not only for his electrifying beats but also for his comedic humor, Dillon has secured his place as a crowd favorite having performed at some of the world’s biggest music festivals, including Coachella, Tomorrowland, and EDC. The combination of top-tier attendees, entertainment, and service promise an exceptional experience that will make it an unforgettable night.The event is co-hosted by 280 Capital, a leading Web3 venture arm with $2 billion in assets under management; Biptap, the first decentralized, non-custody multichain crypto debit card and payment offramp solution; Cytonic, the world‘s first Multi-Virtual-Machine Blockchain, combining Bitcoin, Ethereum and Solana in a single chain; BitcoinOS, the Bitcoin Superchain with interoperable rollups with near trustless rails for BTC & Bitcoin-native assets; and TBV, an early-stage Web3 venture capital fund investing in top-tier projects globally. Supporting partners include ZkPass, LimeWire, 10X Capital, Bitrue, KINO, Ripple,, LBank, ShibaDino, FOMO Ventures, Altcoin Daily, XDC powered by Plug and Play, BoomFi, Hivello, Freename, Aquanow, FunFair Ventures, Petastic, Morningstar Ventures, KXVC and Founders Launchpad.“Web3 with Tobi & Brent” is also supported by prominent players in Web3 PR and media such as yourPRstrategist (YPRS), Cointelegraph, Cryptopolitan, CoinsCapture, Coinstelegram, Luna PR, MediaX Agency, and European Kid as well as community partners like Association Blockchain Asia, Cryptocurrency PH, Unity Labs, Arts DAO, and Crypto World Community and CryptoMondays Lisbon, which further amplify its reach. With its extensive network and high-profile partnerships, the event stands out as a key highlight of TOKEN2049, attracting industry insiders and enthusiasts alike.Due to the high demand and limited capacity guests are advised to arrive early, with doors opening at 9:00PM, to ensure entry.For more information and to register, visit: https://lu.ma/web3tobiandbrenttoken2049SG For the latest updates, join the Telegram group: https://t.me/+5KzXYg2cridmOGRlAbout Web3 with Tobi & BrentWeb3 with Tobi & Brent is a premier event series in the Web3 community, bringing together key industry figures for networking and collaboration. With a focus on fostering connections and sharing insights, these events serve as a hub for innovation and growth in the blockchain space.Company URL: https://linktr.ee/tobiandbrentContact: skye@tbv.xyzPR Contact: pr@yourPRstrategist.com Copyright 2024 ACN Newswire via SeaPRwire.com.
2nd ASEAN Battery Technology Conference Announces New Collaborations and Expansion to Strengthen Southeast Asia Battery Ecosystem
SINGAPORE, Aug 23, 2024 - (ACN Newswire via SeaPRwire.com) - The 2nd ASEAN Battery Technology Conference (ABTC) returned and strengthened the commitment to develop a close knitted battery development ecosystem among the Southeast Asian countries. Hosted in Singapore this year by the Singapore Battery Consortium at Singapore at the Shangri-La Rasa Sentosa between 21st and 23rd August 2024.The conference is also jointly organised by the alliance of leading battery associations in the region - the Thailand Energy Storage Technology Association, the National Battery Research Institute, the National Center for Sustainable Transportation Technology, NanoMalaysia, and the Electric Vehicle Association of the Philippines.Dr. Pimpa Limthongkul, Co-Chairman of ABTC and President of the Thailand Energy Storage Technology Association, said, "This year we are excited to see the expansion of what we have achieved since we last gathered together last year in Bali. Our alliance has grown from three to now six battery associations in Southeast Asia and we will continue to grow in strength. Witnessing the collaborations between the battery associations, private sector and academia is a celebration of how we are moving forward together to drive innovation for a more connected and eco-friendly future in the region.”On the second day of the conference, over 250 participants and the six leading battery associations in Southeast Asia witnessed the signing of three new Memorandums of Understanding or MoUs that will further the development of batteries in the region. From L to R: Prof. Nonglak Meethong (Professor, Khon Kaen University), Mr. Larry Poon (Business Development Manager, INV CORPORATION PTE. LTD.), Dr. Rezal Khairi Bin Ahmad (CEO, NanoMalaysia Berhad), Mr. Bryan Oh (CEO, NEU Battery Materials Pte Ltd) Mr. Freddie Kim (Managing Director, SAMSUNG SDI SOUTHEAST ASIA), Dr. Sing Yang Chiam, Technical Director Singapore Battery Consortium.Three Memorandums of UnderstandingGigafactory Malaysia (GMSB) and NEU Battery Materials (NEU) to Collaborate on Lithium Battery Recycling DevelopmentThe collaboration will focus on developing “Gigafactory” level operations and manufacturing of innovative battery technologies incorporating nanomaterials for mobility and stationary applications. This collaboration is the progression of the Memorandum of Understanding (“Memorandum”) signed in Bali, Indonesia at the 2023 ASEAN Battery and Electric Vehicle Technology Conference (ABEVTC) to promote cross-country collaboration within ASEAN on battery technology.Singapore-based, NEU, who are specialists in LFP battery recycling will ensure a steady supply of recycled battery material, like lithium carbonate and other metals are made available to GMSB’s Hydrogen-Electric-Vehicle-Battery (HEBATT) Centre for performance testing. GMSB is a subsidiary of NanoMalaysia.The testing of the recycled material is to ensure their viability and sustainability within the Malaysia battery ecosystem, which would expand to localised development of a lithium battery recycling ecosystem for the ASEAN region. NEU and GMSB will facilitate this supply and development based on spent battery material being used in an end-to-end ecosystem.This will also pave the way for the exploration of a joint-development programme for improved recycling efficiency between these two companies.Gigafactory Malaysia Sdn Bhd (GMSB) and Khon Khean University (KKU) to Collaborate on Manufacturing of Cells Developed by GMSBGMSB’s and KKU’s collaboration will leverage their joint expertise and resources, with KKU acting as the outsourced manufacturer for batteries developed by GMSB. The collaboration will also provide knowledge sharing in battery testing and certification that will lead to productivity advancements at GMSB's Hydrogen-Electric-Vehicle-Battery (HEBATT) Centre in Malaysia.This Memorandum of Understanding (MoU) is an extension of an agreement signed at the 2023 ASEAN Battery and Electric Vehicle Technology Conference (ABEVTC) in Bali, which involved key organisations from Singapore, Indonesia, Thailand, Malaysia, and the Philippines.Aligned with the ASEAN Battery Network's mission, this MoU aims to strengthen battery technology development within ASEAN.Institute of Materials Research and Engineering (IMRE), Singapore and INV Corporation to collaborate on Joint Research to Develop Hybrid Battery SeparatorsA Research Collaborative Agreement will be signed between the Institute of Materials Research and Engineering in Singapore and INV to develop the next generation hybrid battery separators, which will address the challenges of safety faced by current rechargeable batteries.This collaboration seeks to play on the strengths and IPs in solid state batteries developed in Singapore. INV is headquartered in Singapore and is the largest battery separator film manufacturer in the world. Its production plants are in Sweden and Malaysia.Samsung SDI Southeast Asia ExpansionSamsung SDI, Korean high performance battery manufacturer began production in Southeast Asia with its first facility in Malaysia in 1992 and built a second plant in Vietnam in 2010. It will also open a second plant in Malaysia in 2025.To better support its customers in the region, it recently opened two sales offices in Vietnam and Singapore, with Singapore as the region sales headquarters for South East Asia.It is also planning to open new sales offices in Malaysia, Indonesia, Thailand and Philippines.Samsung SDI’s core battery product in Southeast Asia is the “Prime Battery for Maximum Experience” or PRiMX for short. PRiMX batteries are high on performance, reliability and safety using high nickel (low cobalt) cathode and silicon anode.As the company's vision, expect to make the world greener and sustainable through innovative technology.Hosting of the ABTC is rotated among the co-organisers. In 2025, TESTA will host the ABTC in Thailand.For more information on the programme agenda, please visit our official site: https://reg.eventnook.com/event/ABTC2024/homeThe conference's anchor sponsor is Hyundai Motor Group Innovation Center Singapore (HMGICS), with the gala dinner sponsored by INV Corporation Pte Ltd.Gold sponsors include Amphenol Communications Solutions, Quantel Pte Ltd, Infineon Technologies Asia Pacific Pte Ltd, and Gotion Singapore Pte Ltd, while silver sponsors are Concord New Energy Group Limited, Kewell Technology Co.,Ltd., Metrohm Singapore Pte Ltd, TME Systems Pte Ltd.Additional sponsors include Samsung SDI Southeast Asia Pte. Ltd, Siemens Industry Software Pte Ltd, UL Standards & Engagement, and NEWARE Technology Limited. Publicity partners are the EV Association of Singapore, EV Association of Malaysia, and Turn Off Turn On Ventures.Media ContactPRecious Communicationsabtc@preciouscomms.comAbout ASEAN Battery Technology ConferenceASEAN Battery Technology Conference (ABTC) stands out as the premier battery conference in ASEAN, attracting an audience of over 250 participants. We look forward to engaging with a diverse range of participants, including cell manufacturers, pack integrators, and recycling companies. The mission of ABTC is to bring together regional battery expertise, creating unique opportunities within the global battery value chain.The primary objective of ABTC is to foster collaboration among stakeholders in the battery industry. We aim to facilitate insightful discussions covering various topics, such as advanced battery materials, prototyping, cell-to-pack technologies, and recycling strategies.In addition to these focal points, the conference will explore related aspects such as standards, interoperability, and the ongoing evolution of battery safety technology.Organisers of ABTCAbout Singapore Battery ConsortiumSingapore Battery Consortium (SBC) aims to foster strategic R&D partnerships amongst public research performers and industry players in developing and advancing battery technologies. SBC aims to develop and catalyze the local ecosystem in battery-related technologies through this platform. It is hosted at A*STAR and supported by the National Research Foundation Singapore (NRF). Over the past decade, commercial interest in battery development has been on the rise, keeping pace with demand for better battery performance and different performance characteristics for increasingly complex mobility and portable devices. To meet this demand, the Singapore Battery Consortium will bring research outcomes from our laboratories into the market by enabling researchers to understand business requirements, while giving companies access to the latest battery research and technologies to augment their product development efforts.About Thailand Energy Storage Technology Association (TESTA)TESTA or THAILAND ENERGY STORAGE TECHNOLOGY ASSOCIATION aims to help connect stakeholders, educate the public, promote understanding, and nurture technological advancements in energy storage technologies in Thailand. TESTA was officially registered on January 25, 2021, by 5 founding institutes including the National Science and Technology Development Agency (NSTDA), Khon Kaen University (KKU), King Mongkut’s University of Technology Thonburi (KMUTT), King Mongkut’s University of Technology North Bangkok (KMUT-NB), and Electric Vehicle Association of Thailand (EVAT). Over 60 members of the association include energy storage technology enthusiasts from various sectors ranging from academic, research institutes, public sectors, policymakers, and private industries.About National Center for Sustainable Transportation Technology (NCSTT)The National Center for Sustainable Transportation Technology (NCSTT), or Pusat Pengembangan Teknologi Transportasi Berkelanjutan, is from Indonesia and is a unique multidisciplinary research center focused on conducting, supporting and encouraging applied engineering and technology for transportation systems in Indonesia. NCSTT has been recognized globally as the research center which aims to foster the national transportation industry in developing national economics and welfare. NCSTT has built network linkages and research collaborations with national transportation stakeholders such as automotive, railway and aircraft industries, as well as research institutions and universities.About National Battery Research Institute (NBRI)The National Battery Research Institute (NBRI) was legally established on 17th December 2020 as The Center of Excellence Innovation of Battery and Renewable Energy Foundation, with Prof.Dr. Evvy Kartini as a Founder and Prof Alan J. Drew as Co-Founder. NBRI is Indonesia’s independent institute for electrochemical energy storage science and technology, supporting research, training, and education. NBRI aims to contribute to the overall research capacity and training environment in Indonesia in Battery Research. NBRI is a platform that brings together scientists, academicians, industry partners, the government and all stakeholders that focus on battery technology. The main goal of NBRI is to encourage and support a battery manufacturing industry using local resources, which will enable Indonesia to be independent in energy. The NBRI was supported by the UK Government’s Global Challenge Research Fund (GCRF), part of the Queen Mary University of London QR allocation.About Electric Vehicle Association of Philippines (eVAP)eVAP envisions a nation wherein the use of electric vehicles is highly promoted, encouraged and supported by its government and society to develop a transportation landscape that is one with the environment ecologically and economically. eVAP’s mission is to educate the public on environmental awareness, and the economic and ecological benefits of electric vehicles through the conduct of and/or participation in promotional activities.eVAP aims to accelerate society’s conversion from using gas-powered vehicles to electric vehicles and works with the government in the creation and implementation of legislation that will support and encourage the use of electric vehicles.About NanoMalaysiaNanoMalaysia Berhad was incorporated in 2011 as a company limited by guarantee (CLBG) under the Minister of Science, Technology and Innovation (MOSTI) to act as a business entity entrusted with nanotechnology commercialization activities. Some of its roles include commercialization of nanotechnology research and development, industrialization of nanotechnology, facilitation of investments in nanotechnology and human capital development in nanotechnology. Copyright 2024 ACN Newswire via SeaPRwire.com.
Avantor Triumphs with Three Awards at Korea Biopharma Excellence Awards 2024
Seoul, Korea, Aug 23, 2024 - (ACN Newswire via SeaPRwire.com) - Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences advanced technologies industries, has secured three prestigious awards at the esteemed Korea Biopharma Excellence Awards (KBEA) 2024. The KBEA event, held in conjunction with the 13th Annual Biologics Manufacturing Korea & 6th Vaccine World East Asia 2024 on 13-14, August 2024, underscores Avantor’s exceptional achievements in downstream processing and single-use systems, as well as its leadership as a biopharma supplier in Korea.Left: Andrew Wong, Chief Executive Officer/General Manager of Shanghai Wotai Biotechnology, ChinaRight: James Hwang, Head - Biopharma Applications, AMEA, AvantorAvantor received the following awards:Best Bioprocessing Supplier Award: Downstream ProcessingBest Bioprocessing Supplier Award: Single Use SystemsOverall Biopharma Supplier of the YearThese accolades highlight Avantor's commitment to excellence and innovation in bioprocessing. The "Best Bioprocessing Supplier Award: Downstream Processing" acknowledges Avantor's products and solutions that enhance the efficiency and effectiveness of downstream processing in biopharmaceutical manufacturing. Supporting this success is Avantor's Korea Innovation Customer Support Center (ICSC), which serves as a hub of scientific collaboration and innovation. The ICSC team collaborates closely with customers, offering services that help improve yields, reduce production costs, and ensure efficient production.The "Best Bioprocessing Supplier Award: Single Use Systems" recognizes Avantor's pioneering single-use solutions for strengthening production capabilities, streamlining operations, and improve scalability for biopharmaceutical companies. Notably, this marks the fourth consecutive year that Avantor has received the "Best Bioprocessing Supplier Award: Single Use Systems," following wins in 2022, 2021, and 2020.The "Overall Biopharma Supplier of the Year" award is a testament to Avantor's comprehensive impact on the biopharma industry, reflecting the company's dedication to providing high-quality products and services that drive advancements in biopharmaceutical research and production.Jin Young Lee, Head, Biopharma, APAC, Avantor, expressed his gratitude for the recognition, stating, "We are incredibly honoured to receive these prestigious awards at the Korea Biopharma Excellence Awards 2024. These accolades underscore our relentless commitment to innovation and excellence in bioprocessing and reinforces our standing as a premier supplier in the biopharma industry. They are a testament to the hard work and dedication of our team in Korea, who strive to deliver solutions that enable our customers to deliver life-changing therapies to the patients who need them."James Hwang, Head of Biopharma Applications, AMEA, Avantor commented on the awards and said, “Receiving these awards is a testament to our relentless dedication to advancing bioprocessing capabilities. Our commitment to innovation is embodied in the work we do at the Korea Innovation Customer Support Center (ICSC). Our dedicated team of scientists and application experts at the ICSC help customers with process optimisation, troubleshooting, new product proof of concepts, and hands-on trainings to meet their evolving needs. These awards not only recognize our achievements but also highlight the importance of collaboration and customer-centricity in advancing the biopharma industry.”Avantor's recognition at the Korea Biopharma Excellence Awards 2024 follows its recent success at the Asia-Pacific Biopharma Excellence Awards 2024, where the company won five awards, further solidifying its leadership position in the biopharmaceutical industry.About AvantorAvantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visitavantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.Regional Media Contact::Swati ChhabraManager - Corporate Communications, AMEAAvantor91-9958-404-334swati.chhabra@avantorsciences.comGlobal Media Contact:Eric Van ZantenHead - External CommunicationsAvantor1-610-529-6219eric.vanzanten@avantorsciences.com Copyright 2024 ACN Newswire via SeaPRwire.com.
MVL Launches TADA mini Beta: Ride-Hailing Available via Telegram
Seoul, Korea – August 23, 2024 – (SeaPRwire) – MVL, led by CEO Kay Woo, has announced the beta launch of TADA mini, an innovative ride-hailing service that leverages Telegram bots. While the official launch is scheduled for early September, MVL is hosting a special airdrop event to celebrate this launch. TADA mini is the first real-world utility service for the Web3 world, allowing users to book rides directly through Telegram without the need for additional apps or complicated authentication processes. In addition to ride-hailing, the TADA mini app offers a wide array of features, including multiple vehicle options, live driver tracking, and trip-sharing capabilities. By linking TADA’s network of nearly 300,000 drivers with Telegram’s 900 million users, TADA mini enables seamless real-time communication. Users of the TON blockchain can even request rides through their Tonkeeper wallets, with refunds processed directly to their blockchain wallet in case of cancellations or issues. Currently, TADA mini is in the final stages of testing and will be officially launched to all users in Singapore in early September. The service will also play a key role in providing on-site transportation for Token 2049, the world’s leading cryptocurrency event, taking place in the third week of September. In celebration of TADA mini’s launch, MVL is hosting a referral event for Web3 users, offering 50 million MVL tokens as rewards. Participants can earn mission points by engaging with chatbots, following social media channels, and inviting friends. These points will later be airdropped as MVL tokens after the event concludes. TADA Mini offers real-time ride-hailing and mission features, all easily accessible through this link: https://t.me/TADA_Ride_Bot . MVL’s representative stated, “TADA mini is set to become a significant player in the industry by enhancing the usability of ride-sharing services through integration with Web3 projects. Following the initial launch in Singapore, we plan to expand the service to Cambodia, Vietnam, Thailand, and other countries.” About MVL MVL is committed to driving innovation in the mobility sector through blockchain technology. The company operates real-world mobility services across Asia, including TADA, the second-largest ride-sharing platform in Southeast Asia, and ONiON Mobility, a brand focused on electric vehicles and infrastructure. Building on these services, MVL is developing projects like MVL-Fi, which focuses on sharing mobility value, and DePIN, which is centered on data sharing. Social Links Facebook: https://www.facebook.com/mvlchain X: https://twitter.com/mvlchain YouTube: https://www.youtube.com/channel/UCWIwx5KcQIaf7Ti6piFhnKw LinkedIn: https://www.linkedin.com/company/mvlchain/ Media Contact Brand: MVL Contact: Rose Purevdorj E-mail: mvlsupport@mvlchain.io Website: https://mvlchain.io SOURCE: MVL The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
Hitachi High-Tech Launches New Tabletop Microscopes with Enhanced Usability: TM4000PlusIII and TM4000III
TOKYO, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Hitachi High-Tech Corporation announced today the global launch of TM4000PlusIII and TM4000III Tabletop Microscopes equipped with support features for automation and stable operation.The TM Series shrinks the electron microscope to a size capable of being mounted on a tabletop. Thanks to theircompact size and ease of installation, desktop microscopes are widely used not only for R&D, but also in quality controlat manufacturing sites, science education at schools, and other purposes. In manufacturing environments in particular, there is a need to increase the efficiency of observation tasks and streamline operations so that even users with limited expertise can easily observe a large number of samples.The TM4000PlusIII is equipped with automation support features that enable users to create recipes for numerous conditions. Recipes can control functions such as stage position adjustment and magnification, which previouslyneeded to be manually configured every time for each sample. In addition, they come equipped with maintenance features designed to facilitate consistent observation. One such function is a monitoring system that checks the condition of the tungsten filament* and graphically reports its condition. Since tungsten filaments require regular replacement, this function allows users to track the filament lifetime and plan ahead with maintenance tasks to allow for smooth and consistent operation of the tool.*Tungsten filaments: A single part used in the electron gun of an electron microscope. They are typically made by bending a thin wire made of tungsten (element symbol: W), which is a highly heat-resistant metal, into a hairpin-like shape and connecting it to an electrode. The tungsten filament emits an electron beam when heated.Product Development BackgroundBecause the TM Series makes it possible to conduct high-precision observation and analysis, even when installationspace is limited, it has come to be a critical tool during the development and quality control of new materials. Recently, the TM Series has contributed to conserving the environment and maintaining people’s health by being used to develop environmentally friendly materials and their manufacturing processes, as well as analyze harmful substances in the atmosphere. In manufacturing environments, the trend of decreasing feature size and stricter quality control has led to an increase in the number of SEM users. However, not all new users have specialized knowledge and operatingskills. Amidst this trend, we developed the TM4000PlusIII and TM4000III to have this sought-after optimization and simplification of observation tasks for the purposes of enabling the acquisition of high-precision data without any variability, regardless of who is operating the microscope or their level of expertise.Key Features1. Making Tasks More EfficientThe automation support feature with the TM4000PlusIII allows for observation procedures, such as stage movement, magnification changes, and imaging, to be saved as recipes. They can then be executed to run automatically with a single click. This makes operations more efficient and standardizes techniques among users. This is beneficial for those looking to automate routine tasks and for users who are concerned about having to manually configure observation conditions.The TM4000PlusIII also features a setting for high-current mode which enables faster operations due to the increasedobservation signal. For example, in particle analysis a large number of measurement points are required which can bevery time consuming to collect. The high-current function shortens measurement time for each location while reducing the overall time involved in such tasks.2. Plan Ahead with the Filament Monitoring FunctionThe microscopes come equipped with new support features to ensure they can be used with peace of mind at all times. One example is the filament indicator feature, which allows users to track the filament life on screen, preventinginstances of observations being interrupted due to filament replacements occurring mid-observation.3. Ideal for Educational PurposesThe TM Series is equipped with low-vacuum and high-sensitivity backscattered electron detectors, which eliminate the need for complicated pretreatment processes. This makes it possible to conduct observations on a variety of sampleswith ease, enabling the TM Series to be utilized in educational settings.Additionally, as digital skill development becomes a critical subject in educational settings, the TM4000PlusIII allowusers to experience and learn important programming concepts such as “sequential execution,” “repetition,” and “conditional branching” via the automation support features.The TM4000PlusIII and TM4000III will be exhibited at JASIS 2024 at the Makuhari Messe International ExhibitionHalls in Chiba, Japan, from September 4 through September 6, 2024.Hitachi High-Tech aims to ship a target total of 6,000 TM Series units across the global market as quickly as possible to contribute to manufacturing worldwide. Hitachi High-Tech will continue to refine our core analysis technologies, and provide measurement and inspection solutions that support R&D and quality control operations in a wide range of fields, in order to help improve people's QoL (Quality of Life) and to resolve social issues related to the environment, resilience, and security and safety.About Hitachi High-TechHitachi High-Tech, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, includingmanufacture and sales of clinical analyzers, biotechnology products, radiation therapy systems, semiconductor manufacturing equipment, analytical instruments, and analysis equipment. Also, we provide high value-added solutions in industrial fields such as mobility, connected, environment and energy, etc. Through business based on our core Observation, Measurement and Analysis technologies, we will contribute to the realization of a sustainable society by solving social issues.The company's consolidated revenues for FY2023 were approx. JPY 670.4 billion. For further information, visit www.hitachi-hightech.com/global/en/Business Contact:Takeshi KamimuraGlobal Sales Planning Dept.Beam Technology & Analytical Systems Business Div., Core Technology & Solutions Business GroupHitachi High-Tech CorporationEmail: takeshi.kamimura.jj@hitachi-hightech.com Copyright 2024 JCN Newswire via SeaPRwire.com.
百年來最大鑽石在波札那出土，重達 2,492 克拉
(SeaPRwire) - 加博羅內，波札那（美聯社）—— 在波札那的一處礦場中，發現了超過一個世紀以來最大的鑽石，該國總統在週四的觀禮儀式上向世界展示了這顆拳頭大小的寶石。 波札那政府表示，這顆重達 2,492 克拉的巨石是史上第二大礦場發現的鑽石。這是自 1905 年以來發現的最大鑽石。 這顆尚未命名的鑽石在波札那總統莫克韋茨·馬西西的辦公室向全世界展示。它重約半公斤，馬西西是第一批握住它的人之一。 官員表示，現在評估其價值或決定如何出售還為時過早。2016 年，波札那同一礦場的另一顆較小的鑽石以 6300 萬美元的價格售出，創下了原石的價格紀錄。 「這是歷史性的時刻，」Lucara Diamond Corp.（一家在波札那擁有管理職位的加拿大礦業公司）的波札那常務董事納西姆·拉赫里說。「我感到非常自豪。這是波札那的產品。」 Lucara 在週三的一份聲明中表示，他們從位於波札那中部的卡羅威礦場開採出這顆「非凡」的原鑽。Lucara 表示，這是一顆「高品質」的鑽石，並且完整無缺地被發現。它是使用旨在尋找大型鑽石的 X 光技術定位的。 「我們對開採出這顆非凡的 2,492 克拉鑽石感到興奮，」Lucara 總裁兼首席執行官威廉·蘭姆在一份聲明中說。 它的重量將使其成為 119 年來發現的最大鑽石，也是繼 1905 年在南非發現的庫利南鑽石之後，從礦場開採出來的第二大鑽石。著名的庫利南鑽石重達 3,106 克拉，被切割成寶石，其中一些是英國皇冠珠寶的一部分。 在 19 世紀後期，巴西發現了一顆更大的、純度較低的黑色鑽石，但它是從地表發現的，據信是來自一顆隕石的一部分。 波札那是位於非洲南部的擁有 260 萬人口的國家，是僅次於俄羅斯的第二大天然鑽石生產國，近年來開採了世界上所有最大的鑽石。在過去十年中，卡羅威礦場開採出了另外四顆超過 1,000 克拉的鑽石。 在這次發現之前，2019 年在卡羅威礦場發現的塞韋羅鑽石被認為是世界上第二大開採出來的鑽石，重達 1,758 克拉。它被法國時尚品牌路易威登以未公開的價格買下。 來自波札那卡羅威礦場的 1,111 克拉的雷塞迪拉羅納鑽石於 2017 年被英國珠寶商以 5300 萬美元的價格買下。另一顆來自卡羅威的鑽石「星座」以創紀錄的 6300 萬美元的價格售出。 鑽石是在地下深處高壓下將碳原子擠壓在一起時形成的。科學家說，大多數鑽石至少有 10 億年的歷史，有些甚至超過 30 億年。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
珍妮佛·洛佩茲 申請離婚後，班·艾佛列克 在民主黨全國代表大會意外被提及
(SeaPRwire) - 演員兼導演班·艾佛列克在星期三晚上於芝加哥舉行的民主黨全國代表大會上意外被提及。這段意外的致敬發生在演員兼編劇敏蒂·卡靈（以《辦公室》和《敏蒂計畫》聞名）登上舞台時。卡靈參加大會是为了谈论她与民主党总统候选人、副总统卡瑪拉·賀里斯的友谊，但她也花了一些时间来庆祝她自己的家乡马萨诸塞州。 “我不能离开这里而不向我来自的州、马萨诸塞州的优秀代表团表示感谢。我爱你们，马萨诸塞州。每个人都在批评我们。但他们不明白。加油紅襪！加油杰森·塔图姆，”她说。“班·艾佛列克，坚持住！Dunkin' Donuts是世界上最好的咖啡。” 敏蒂·卡靈在民主黨全國代表大會上表達了她對馬薩諸塞州的感謝，並向班·艾佛列克致敬：“堅持住！” 艾佛列克經常在 中 出現，他也以對 Dunkin' Donuts 的喜愛而聞名。他曾出演過多支廣告，包括 一支他演唱跳舞的廣告。珍妮佛·羅培茲也與 和足球四分衛湯姆·布雷迪（他曾為波士頓的紐英格蘭愛國者隊效力）一起出演了這支廣告。 艾佛列克在民主黨全國代表大會上的提及，恰好是在羅培茲正式向艾佛列克提出離婚申請的第二天。 在 2000 年代初期，他們曾 ，但最終在 2004 年 1 月宣布結束關係，部分原因是來自大眾的壓力。在 2021 年，他們重燃愛火的傳聞開始流傳，他們多次被拍到一起出現，並共同參加紅毯活動。在 2022 年，這對夫婦訂婚並隨後結婚。“愛是美好的。愛是善良的。事實證明，愛是耐心的。二十年的耐心，”羅培茲 在 2022 年 7 月宣布他們在拉斯維加斯結婚時說。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
Leqembi (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain
TOKYO and CAMBRIDGE, Mass., Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Aβ) monoclonal antibody “Leqembi®” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain.1 Lecanemab is indicated for the treatmentof mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein Eε4 (ApoE ε4)* heterozygotes or non-carriers.1 Lecanemab becomes the first treatment for early AD (MCI and mild dementia due to AD)2 that targets an underlying cause of the disease, to be authorized in a country in Europe.1Lecanemab selectively binds to Aβ aggregate species, with preferential activity for toxic Aβ protofibrils** (as well as fibrils, which are a major component of Aβ plaques).2,3,4 It binds to these aggregate Aβ species to neutralize and clear them from the brain.2,3,4The approval was primarily based on Phase 3 data from Eisai’s global, placebo-controlled, double-blind, parallel-group, randomized Clarity AD clinical trial, in which the medicine met its primary endpoint (change from baseline in the Clinical Dementia Rating Sum of Boxes [CDR-SB]† at 18 months) and all key secondary endpoints with statistically significant results.2 Inthe indicated population in Great Britain, the most common adverse reactions were infusion-related reaction, amyloid-related imaging abnormalities with hemorrhage (small spots of bleeding) (ARIA-H)‡, fall, headache and amyloid-related imaging abnormalities with cerebral edema (build-up of fluid) (ARIA-E)‡‡.1In the United Kingdom, it is estimated that 982,000 people are living with dementia,5 and AD is the cause in 60-70% of people with dementia.6 These numbers are expected to rise, as the population ages.5,6Eisai is working collaboratively with the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the National Health Service (NHS) to make this medicine available to eligible people living with early AD as soon as possible.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In Great Britain, Eisai and Biogen will co-promote the medicine, with Eisai distributing the product as the Marketing Authorization holder.*Apolipoprotein E is a protein involved in the metabolism of fats in humans. It is implicated in AD.**Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms. 7 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.8†CDR-SB is a commonly used diagnostic tool, which can help to stage dementia due to AD.9 It is a global cognitive and functional scale that measures six domains of functioning, including memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care.9‡ARIA-H: amyloid-related imaging abnormalities with hemorrhage (microhemorrhages, and superficial siderosis).‡‡ARIA-E: amyloid-related imaging abnormalities with oedema (edema/effusion).More information can be found in the Summary of Product Characteristics and Patient Information leaflets which will be published on the MHRA Products website within 7 days of approval.MEDIA CONTACTSEisai Co., Ltd.Public Relations Department TEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 7974-879-419Emea-comms@eisai.netBiogen Inc.Jack Cox+ 1-781-464-3260public.affairs@biogen.comEisai Inc. (U.S.)Libby Holman1-201-753-1945Libby_Holman@eisai.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations Department TEL: +81 (0) 3-3817-5122Biogen Inc.Chuck Triano+ 1-781-464-2442IR@biogen.comAbout lecanemab (Leqembi®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).2,3Lecanemab’s approval in Great Britain was primarily based on Phase 3 data from Eisai’s global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results.1,2 Clarity AD was a Phase 3global, placebo-controlled, double-blind, parallel-group, randomized study in 1,795 patients with early AD (MCI or milddementia due to AD, with confirmedpresence of amyloid pathology), of which 1,521 were in the indicated population in the label in Great Britain (ApoE ε4heterozygotes or non-carriers).1 Of the total number of patients randomized 31% were non-carriers, 53% were heterozygotes and 16% were homozygotes.1 The treatment group was administered lecanemab 10 mg/kg bi-weekly, with participants allocated in a 1:1 ratio to receive either placebo or lecanemab for 18 months.1The primary endpoint was the global cognitive and functional scale, CDR-SB.1 In the Clarity AD clinical trial, treatment with lecanemab, in the indicated population in Great Britain (ApoE ε4 heterozygotes or non-carriers), reduced clinical decline on CDR-SB by 33% at 18 months compared to placebo.1 The mean CDR-SB score at baseline was approximately 3.2 in both groups.1 The adjusted least-squares mean change from baseline at 18 months was 1.15 with lecanemab and 1.73 with placebo(difference, −0.58; 95% confidence interval [CI], −0.81 to −0.34; P<0.00001).1 CDR-SB is a global cognitive and functional scale that measures six domains of functioning, including memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care.9In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted 39% less decline compared to placebo at 18 months.1 The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADLscore was −3.5 in the lecanemab group and −5.7 in the placebo group (difference, 2.2; 95% CI, 1.3 to 3.1; P<0.00001).1 The ADCS-MCI-ADL assesses the ability ofpatients to function independently, including being able to dress, feed themselves and participate in community activities.In the indicated population (ApoE ε4 heterozygotes or non-carriers), the most common adverse reactions were infusion-related reaction (26%), ARIA-H (13%), fall (11%), headache (11%) and ARIA-E (9%).1Lecanemab is licensed in the U.S., 10 Japan, 11 China, 12 South Korea, 13 Hong Kong, 14 Israel, 15 the United Arab Emirates16 and Great Britain1 and marketed in the U.S., Japan and China. Eisai has also submitted applications for approval of lecanemab in 10 countries and regions, including the European Union.This medicine is subject to additional monitoring. This will allow quick identification of new safety information.About NHS, NICE and SMCThe NHS is a public healthcare system with the principle of providing free medical services to citizens. The NICE and the SMC are independent bodies that carry out assessments on the status of all newly licensed medicines, all new formulations of existing medicines and new indications for established products regarding their health benefits and price justification as advisory boards to the NHS about whether or not a newly licensed drug should be accepted for use under national health insurance.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisaiserves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on theantibody back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities,manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us onX, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com.Follow Biogen on social media – Facebook, LinkedIn, X, YouTube. The website and social media channels are intended for audiences outside of the UK and Europe.Biogen Safe HarborThis news release contains forward-looking statements, about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; thetreatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs; including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small numberof research and development programs result in commercialization of a product. Results in early-stage clinical studies may notbe indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatoryauthorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates; including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of the medicine; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertaintiesrelating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results ofoperationsand financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ fromBiogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the riskfactors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securitiesand Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake anyobligation to publicly update any forward-looking statements.(1) Lecanemab Great Britain Summary of Product Characteristics(2) van Dyck, H., et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine.2023;388:9-21. https://www.nejm.org/doi/full/10.1056/NEJMoa2212948.(3) Johannesson, M., et al. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains. Molecular and Cellular Neuroscience. 2024;130:103949. https://doi.org/10.1016/j.mcn.2024.103949.(4) Sehlin, D., et al. Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012;7(2):e32014. https://doi.org/10.1371/journal.pone.0032014.(5) Alzheimer’s Society. 2024. The economic impact of dementia. Available at: https://www.alzheimers.org.uk/about-us/policy-and-influencing/dementia-scale-impact-numbers. Last accessed: August 2024.(6) World Health Organization. 2023. Dementia. Available at: https://www.who.int/news-room/fact- sheets/detail/dementia. Last accessed: August 2024(7) Amin, L., Harris, D.A. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxicoligomers. Nature Communications. 2021;12:3451. doi:10.1038/s41467-021-23507-z. (8) Ono, K., Tsuji, M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. International Journal of Molecular Sciences. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.(9) Morris, J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.(10) U.S. Food and Drug Administration. 2023. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval. Last accessed: August 2024.(11) Reuters. 2023. Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen. Last accessed: August 2024.(12) The Pharma Letter. 2024. Brief - Alzheimer drug Leqembi now approved in China. Last accessed: August 2024.(13) Pharmaceutical Technology. 2024. South Korea’s MFDS approves Eisai-Biogen’s LEQEMBI for Alzheimer’s. Last accessed: August 2024.(14) Pharmaceutical Technology. 2024. Hong Kong approves Leqembi for Alzheimer’s treatment. Last accessed: August 2024.(15) BioSpace. 2024. Leqembi approved for the treatment of Alzheimer’s disease in Israel. Last accessed: August 2024.(16) United Arab Emirates Ministry of Health & Prevention. 2024. Registered Medical Product Directory. Leqembi. Last accessed: August 2024. Copyright 2024 JCN Newswire via SeaPRwire.com.
Datacentre & Cloud Infrastructure Summit (DCCI) gears up to transform the Kingdom’s digital future
Riyadh, Saudi Arabia, Aug 22, 2024 - (ACN Newswire via SeaPRwire.com) - Having debuted in Saudi Arabia last year, Datacentre & Cloud Infrastructure Summit (DCCI) is pacing for a massive return to the country on 5 – 6 November 2024 at the luxurious JW Marriott Hotel in Riyadh. Poised to gather over 300 industry leaders, experts, and key decision-makers from across the country, the platform will delve into the latest trends, innovations, ground-breaking strategies and give a pulse of the Kingdom’s datacentre & cloud landscape.With global industries expanding their footprint in the Kingdom, cutting-edge events in Riyadh have become a regular phenomenon. In line with VISION 2030, DCCI aims to upgrade the Kingdom’s technology stance by bringing global expertise closer to its datacentre & cloud ecosystem that is pivotal for a diversified economy and paramount to its digital future.To share the latest updates concerning Saudi’s digital infrastructure especially from its datacentres & cloud landscape, DCCI is bringing none other than the top officials from the leading public & private organisations including but not limited to the Ministry of Saudi Arabia National Guard, Saudi Olympic & Paralympic Committee, Saudi Pro League, Saudi Basic Industries Corporation (SABIC), Saudi Entertainment Ventures and Saudi Payments.These officials are not just the leading voices from across sectors but also the embodiment of progress who will be seen taking insightful keynote sessions, engaging fireside chats and deep dive panel discussions on the most pressing topics.Some prominent topics from the summit include, ‘Revolutionizing Saudi Arabia's Digital Infrastructure Landscape’, ‘National Data Sovereignty and Upholding Data Privacy’, ‘A Cloud-Powered Future for a Digital Saudi Arabia’, ‘Reimagining Data Centre Cooling’, ‘Reengineering Data Architecture’, ‘Empowering Next-Generation data centres through AI-Powered Infrastructure’, ‘Sustainable and Green Data Centres for a Digital Saudi Arabia’ and others.Attendees will also get the opportunity to explore the latest datacentre and cloud solutions as the platform will feature a stellar lineup of solution providers including but not limited to Edarat, Legrand Data Center Solutions, Daikin Air Conditioning Saudi Arabia, C&D Technologies, Corning, Hasoub, Austin Hughes, Nlyte Software, Sunbird Software, SETRA, Belden, Rittal, and many more.During the course of two days, DCCI will present an unparalleled opportunity to learn the latest intel, shake hands and network with industry’s very best, have one-on-one interactions with hand-picked profiles and last but not least forge strategic partnerships for growth & development.Organiser and CEO of Tradepass, Sudhir Ranjan Jena stated his organisation’s exemplary vision behind bringing this platform to the Kingdom, “The Datacentre & Cloud Infrastructure Summit (DCCI) is an effort towards powering an era that comes entwined with progress and global collaborations. With a focus on Saudi Arabia’s booming digital infrastructure landscape, DCCI will be a cornerstone for driving the latest datacentre & cloud innovations in the country that’s intrinsic to the Kingdom’s post-oil economy.”About TradepassProviding access to the global emerging markets, Tradepass brings together people, products and solutions to power events for unparalleled business and networking opportunities. Being the most accredited event company, it helps organizations: enter new markets, grow sales pipeline, close prospects, raise capital and identify the right solution-providers.As a deal facilitator, Tradepass is always determined about exposing the most agile liquid growth markets, to enable all-round scalability and growth.For more information about the event, log on to:https://saudi.dccisummit.com/Media contact:Shrinkhal SharadPR & Communication Leadinfo@tradepassglobal.com+ (91) 80 6166 4401Tradepass Copyright 2024 ACN Newswire via SeaPRwire.com.
GR Supra GT4 EVO2 Launched for 2025 Season
Toyota City, Japan, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - TOYOTA GAZOO Racing (TGR) began accepting orders today for the new GR Supra GT4 EVO2, for which vast feedback from racing teams and drivers around the world was leveraged to achieve higher levels of performance, reliability, and operability.Since the launch of the GR Supra GT4 in 2020, thanks to the support of race organizers and customers, cumulative sales(1) of the model have surpassed 120 units. The efforts of racing teams and drivers have enabled it to win GT4-series races and international races in 11 countries and regions, earn more than 500 podium finishes(2), and become the class champion in three regions: Asia, the United States, and Europe.An updated GR Supra GT4 EVO for the 2023 season featured improved braking, handling, and engine performance, making the car easier to drive for drivers of various skill levels. Yet, after that update, with there being no end to its efforts to make ever-better motorsports-bred cars, TGR continued to travel to race tracks around the world to directly receive valuable feedback from racing teams and drivers that can only be obtained under the extreme conditions of racing. Advancing its "driver-first car-making" approach for leveraging such insights into development, TGR has set the race debut of the GR Supra GT4 EVO2, with improved performance, reliability, and operability, at the start of the 2025 season.Specifically, ABS maps were meticulously re-tuned through driving by various drivers on circuits in Japan and Europe to enable optimal braking and cornering based on tire type and wear and the condition of the course. Additionally, downshifting time has been reduced by fine-tuning the rev matching through a software update, leading to enhanced deceleration control during braking for increased cornering speed. Also, in addition to improving the cooling performance of the engine, brakes, and drivetrain, cockpit temperatures have been optimized to make the car easier to drive even in harsh conditions, helping to maintain a high level of performance. These improvements make the GR Supra GT4 EVO2 easier to drive not only for professional racers but also for amateur drivers ambitiously competing in GT4 races worldwide.The GR Supra GT4 EVO2 is scheduled to make its world debut in January 2025 in the first round of the IMSA Michelin Pilot Challenge, held in conjunction with the 24 Hours of Daytona.GT4 sales and customer support (spare parts sales and technical support) will be handled by TOYOTA GAZOO Racing Europe GmbH in Europe, TRD U.S.A., Inc. in North America, Toyota Customizing and Development Co., Ltd. in Japan and other countries in Asia (excluding China), and Toyota Motor (China) Investment Co., Ltd. in China.(1) Including the GR Supra GT4 EVO(2) As of the end of July 2024For more information, visit https://global.toyota/en/newsroom/toyota/41393991.html. Copyright 2024 JCN Newswire via SeaPRwire.com.
MHI Begins Joint Demonstration with Kirin Group for Automation of Inbound and Outbound Warehouse Processes, and Loading and Unloading of Trucks
TOKYO, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI), together with Kirin Group companies Kirin Beverage Co., Ltd. and Kirin Group Logistics Co., Ltd., in August will begin a joint demonstration aimed at establishing elemental technologies for the automation of inbound and outbound processes at beverage warehouses, and the loading and unloading of trucks. The joint demonstration will be conducted at LogiQ X Lab, a demonstration facility located within Yokohama Hardtech Hub (YHH), MHI's co-creation space in Honmoku, Yokohama, and at Kirin Group Logistics sites. The demonstration is scheduled to conclude by March 2026.For this demonstration, as part of the "Smart Connections" solutions incorporating the ΣSynX (Sigma Syncs) technology(Note1) that MHI is currently researching and developing, MHI will utilize a new type of unmanned forklift that is currently under development equipped with ΣSynX, with the aim of establishing elemental technologies that enable flexible autonomous operation and safe human-machine coordination, including appropriate load assortment in warehouse work, altering of operational routes in response to changes in placement locations and storage conditions, and highly efficient storage methods. Through this joint demonstration, MHI aims for future automation of the entire cargo handling process, from the unloading of trucks to handling of inbound and outbound warehouses process, and loading onto trucks.MHI is steadily advancing efforts to utilize "Smart Connections" solutions incorporating the ΣSynX (Sigma Syncs) technology for automation and intelligence of normal logistics warehouse work, which up to now has been conducted safely and efficiently through the expertise, experience and skills of operators, focusing on the three areas of picking, inbound and outbound processes, and the loading and unloading of trucks. Following picking, which is the handling of cargo in warehouses, MHI will pursue development and verification to support the implementation of "Smart Connections" solutions for warehouse operations in the logistics industry. MHI and Kirin Group conducted a joint demonstration of automated picking from November 2022 to June 2023.(Note2) This demonstration verified its effectiveness at logistics sites, and an automated picking solution is scheduled to start operation at Kirin Group's Ebina Logistics Center in Kanagawa Prefecture from December 2024. This new joint demonstration being conducted by the two companies will accelerate the response to the challenges posed to the logistic industry by regulatory changes implemented in 2024.Going forward, through coordination with Kirin Group for this demonstration program, MHI will work to provide solutions for the various issues faced by the beverage industry due to regulatory changes, such as the shortage of logistics operators, the need for improvement in working conditions, and reducing truck driver working hours and wait times.(1) ΣSynX (Sigma Syncs) is MHI's standard platform for synchronizing and coordinating various types of machinery systems. It consolidates a host of digital technologies that enable optimized operation by making machinery systems intelligent. For more information, please refer to the following press release. www.mhi.com/news/23100501.html(2) For more information on the joint demonstration with Kirin Group for an automated picking solution, please refer to the following press release. www.mhi.com/news/22112101.html Overview of the Joint DemonstrationImplementation period: August 2024, through March 2026Demonstration sites: MHI's LogiQ X Lab demonstration facility at Yokohama Hardtech Hub (YHH), MHI's demonstration facility at Kobe Shipyard, and Kirin Group Logistics facilities such as Nishi-Nagoya and Amagasaki.Content for the demonstration- Determining of operational processes, including manned work, assuming the introduction of warehouse inbound and outbound process solutions- Determining of operational processes, including manned work, assuming the introduction of unmanned forklifts for loading and unloading trucks- Determining of safety concepts, rules, operating conditions, and other standards for collaborative work with manned and unmanned forkliftsTags: Sigma SynX,Smart InfrastructureAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.
Techstars Tokyo Accelerator Announces Inaugural Class of 2024
TOKYO, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Techstars Tokyo Accelerator powered by JETRO and Mitsui Fudosan is proud to announce the 12 startups selected for the Class of 2024. These promising, early-stage companies are addressing challenges in categories such as Women’s Health, Gaming, Animation, Productivity Enhancement, B2B Business Intelligence, Robotics and more.Taking place in the rapidly growing tech ecosystem of Tokyo, the three-month mentorship-driven program is bringing together founders from across the globe from countries of Finland, India, Indonesia, U.S. and Vietnam along with six Japanese companies. The 2024 class was chosen for innovative products and solutions in areas that will revolutionize how entertainment industries work, how the companies manage their data, and how people live and work better.“We are thrilled to welcome the very first class of Techstars Tokyo Accelerator program,” said Yuki Shirato, Managing Director at Techstars. “This exceptionally talented and diverse group of founders demonstrates tremendous potential and we’re eager to offer our full support leveraging our network of mentors, investors and talents locally and globally and growth-focused tools and workshops, to propel them towards success.”Demo Day is scheduled on November 12th, 2024, where founders will have an opportunity to pitch their businesses to a community of mentors and potential investors.Introducing our inaugural class for the Techstars Tokyo Accelerator!- Aman (Jakarta, Indonesia)Supercharges customized employee health benefits for micro, small and medium enterprises- Amatama (Nagoya, Japan)Optimizes hierarchical computational technology development for humanoids to completely replace labor- Assethub (California, US)Provides an easy way to create unique 3D models from pictures using AI- Digital Will Inc. (Tokyo, Japan)Democratizes gaming with our AI-enhanced platform, WORTAL, for game developers- Dondon Technologies, Inc. (New Jersey, US)Accelerates 2D anime production with AI-assisted drawing tools- InfraHive (Rajasthan, India)Develops data intelligence for finance, analytics and customer teams of enterprises- March Health (California, US)Revolutionizes women’s health (endometriosis) with an AI-first clinic in your pocket- Pioneerwork (Tokyo, Japan)Automates and expedites dropshipping for retail e-commerce- Samaria Inc. (Tokyo, Japan)Unleashes the potential of Japanese manga to the world with AI- Saner.AI (Ho Chi Minh, Vietnam)Revolutionizes knowledge management for knowledge workers, particularly people with ADHD- StoryDrops (Helsinki, Finland)Builds a platform of authenticity through creating and sharing audio messages- Undesk (Tokyo, Japan)Provides a multi-player browser to improve team communication and productivityAbout TechstarsTechstars is the most active pre-seed investor in the world having invested through its accelerators in more than 3,800 companies. Founded in 2006, Techstars believes that entrepreneurs create a better future for everyone and great ideas can come from anywhere. Now we are on a mission to invest in an unprecedented number of startups per year enabling more capital to flow to more entrepreneurs around the world. We do this by operating accelerator programs and venture capital funds, as well as by connecting startups, investors, corporations, and cities to help build thriving startup communities. www.techstars.comMedia Contact for TechstarsAmalia Lytleamalia.lytle@techstars.com Copyright 2024 JCN Newswire via SeaPRwire.com.
雲頂新耀宣佈 自主研發的新型mRNA個性化腫瘤治療性疫苗正式啟動臨床試驗
上海, 2024年8月22日 - (亞太商訊 via SeaPRwire.com) — 雲頂新耀（HKEX 1952.HK）是一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈正式啟動一款個性化腫瘤疫苗EVM16的研究者發起的臨床試驗項目（IIT）EVM16CX01。該研究由北京大學腫瘤醫院和復旦大學附屬腫瘤醫院發起，用於評估EVM16注射液單藥及聯合PD-1抗體治療在晚期或復發實體瘤受試者的安全性、耐受性、免疫原性和初步療效的劑量遞增及擴展研究。這是EVM16開展的首次人體試驗。EVM16是一款雲頂新耀自主研發的新型mRNA個性化腫瘤治療性疫苗，根據每位患者特有的腫瘤細胞突變，使用自主研發的人工智能算法，預測出具有較高免疫原性潛力的新抗原。通過脂質納米顆粒（LNP）遞送系統在體內進行高效的抗原呈遞，激活新抗原特異性T細胞，進而達到殺傷腫瘤細胞和治療癌症的目的。雲頂新耀首席執行官羅永慶表示：「EVM16是雲頂新耀自主研發的首款個性化mRNA腫瘤疫苗，此次臨床試驗項目的正式啟動意味著公司基於自主知識產權的mRNA平台所開發的腫瘤疫苗產品進入人體試驗階段，有望為腫瘤治療領域開發出新一代免疫療法。在構建腎科、感染、自身免疫性疾病領導地位的同時，雲頂新耀也快速進入腫瘤治療性疫苗等創新性治療領域，開拓新藍海。我們期待早日看到個性化腫瘤疫苗成為新的臨床治療手段，服務更多患者。」Globocan 2022年統計數據顯示，全球新發腫瘤人數1997.6萬人，因腫瘤死亡的人數為974.4萬人1。以PD-1/PD-L1抑制劑為主的免疫療法已經成為某些腫瘤治療非常重要的一部分，但僅對部分患者有效，腫瘤治療領域急需在此基礎上開發新一代免疫療法。個性化mRNA腫瘤疫苗則成為極具潛力的新一代免疫療法。在臨床前研究中，EVM16在多種小鼠模型中都激發出了強烈的新抗原特異性T細胞免疫反應，在小鼠黑色素瘤B16F10模型中實現了顯著的腫瘤生長抑制效果。雲頂新耀自研的算法已找到多個已知和之前未報道的腫瘤抗原，並且在多個獨立驗證研究中的預測表現相當或優於行業領先算法，臨床前數據還證明了EVM16疫苗與PD-1抗體聯用後的協同抗腫瘤效果，支持個性化腫瘤疫苗與免疫檢查點抑制劑在臨床中的聯用。在臨床前安全性評估試驗中，EVM16疫苗也展現了良好的安全性。這些結果綜合說明，EVM16注射液安全性良好，和免疫檢查點抑制劑聯用有望給腫瘤患者帶來更多臨床獲益。雲頂新耀利用自主知識產權的mRNA平台開發預防及治療性的mRNA產品，且擁有這些產品的全部知識產權及全部全球權益，並同時具備治療性mRNA產品全產業鏈的開發和製造能力。自研團隊基於經過臨床驗證的mRNA技術平台，多路徑開發腫瘤及其他治療藥物。目前正在研發多個mRNA腫瘤治療藥物，包括個性化腫瘤疫苗（PCV）、腫瘤相關抗原（TAA）腫瘤疫苗、免疫調節腫瘤疫苗，自體生成CAR-T產品 ，並開發新一代脂質納米粒（LNP）遞送系統以增強細胞介導的免疫反應。此外，雲頂新耀擁有自有商業化規模生產基地，位於浙江嘉善、符合全球良好生產規範（GMP）標準認證的生產基地，於2022年12月正式投入運行並成功完成了臨床批次生產，為實現mRNA技術平台的本土化研發、生產以及商業化運營奠定堅實的基礎。參考文獻：1. Globocan 統計資料: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf關於EVM16EVM16是一款雲頂新耀醫藥科技有限公司自主研發的新型mRNA個性化腫瘤疫苗。EVM16是用菌種庫製備得到的線性化質粒DNA為模版，經體外轉錄、純化、除菌過濾製備出mRNA原液，採用脂質納米顆粒（LNP）技術將mRNA原液包封在由特定脂質組分組成的納米級脂質顆粒中，加入其他輔料經無菌灌裝製成。EVM16根據每位患者獨有的腫瘤細胞突變，使用自主研發的人工智能算法，預測出具有較高免疫原性潛力的新抗原，採用脂質納米顆粒（LNP）遞送系統將能高效表達腫瘤新抗原的mRNA遞送至人體內。受試者接種EVM16注射液後，mRNA被遞送入細胞內生成新抗原肽段，誘導機體產生新抗原特異性的T細胞免疫反應，來殺傷清除表達新抗原的腫瘤細胞而達到抑制腫瘤生長和治療癌症的目的。關於EVM16CX01研究項目此研究是一項評估EVM16注射液單藥及聯合PD-1抗體治療對晚期或復發實體瘤受試者的安全性、耐受性、免疫原性和初步療效的劑量遞增及擴展研究，也是EVM16的首次人體試驗。主要研究目的包括評估EVM16單藥以及EVM16聯合PD-1抗體在晚期或復發性實體瘤受試者中的安全性和耐受性，確定EVM16的II期推薦劑量（RP2D）；次要目的包括評估EVM16在晚期或復發性實體瘤受試者中的免疫原性，以及評估EVM16聯合PD-1抗體在晚期或復發性實體瘤受試者中的初步有效性。關於雲頂新耀雲頂新耀是一家專注於創新藥和疫苗研發、臨床開發、製造和商業化的生物製藥公司，致力於滿足亞洲市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業從事過高質量研發、臨床開發、藥政事務、化學製造與控制（CMC）、業務發展和商業化運營，擁有深厚的專長和豐富的經驗。雲頂新耀已打造多款疾病首創或者同類最佳的藥物組合，公司的治療領域包括腎科疾病、感染性和傳染性疾病、自身免疫性疾病。有關更多信息，請訪問公司網站： www.everestmedicines.com前瞻性聲明本新聞稿所發佈的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用“將”、“預期”、“預測”、“期望”、“打算”、“計劃”、“相信”、“預估”、“確信”及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發佈日後最新信息、未來項目或情形的任何義務，除非法律要求。 Copyright 2024 亞太商訊 via SeaPRwire.com.
Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT)
SHANGHAI, Aug 22, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest”, or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiated Clinical Trial (IIT) for a personalized mRNA cancer vaccine, EVM16, under the study EVM16CX01, at the Peking University Cancer Hospital and Fudan University's Cancer Hospital. This trial is designed to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 injection as a monotherapy and in combination with PD-1 antibody for patients with advanced or recurrent solid tumors. EVM16CX01 is the first-in-human (FIH) trial for EVM16.EVM16 is a novel personalized therapeutic mRNA cancer vaccine independently developed by Everest. EVM16 contains neoantigens with high immunogenicity potential that are predicted based on the unique tumor mutations of each patient by Everest’s proprietary neoantigen prediction algorithm. The vaccine uses a lipid nanoparticle (LNP) delivery system to efficiently deliver neoantigen-encoded mRNA in vivo, activating neoantigen-specific tumor-killing T cells and inhibiting tumor growth."EVM16 is the first personalized mRNA cancer vaccine independently developed by Everest using our proprietary mRNA platform. The initiation of this clinical trial is an important milestone that demonstrates our commitment to discover and develop a new generation of mRNA immunotherapies for cancer and autoimmune diseases.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.“While establishing leadership positions in nephrology, infectious disease, and autoimmune diseases, Everest will also focus on innovative modalities such as therapeutic mRNA vaccines. We look forward to seeing personalized cancer vaccines become a new clinical treatment method to serve more patients."According to the Globocan’s data in 2022, there were 19.976 million new cancer cases globally, with 9.744 million cancer-related deaths1. In the last few decades, Immunotherapy including checkpoint inhibitors has become an important part of treating some cancer types. However, they are only effective for some patients, and there is an urgent need to develop new generations of immunotherapies, such as personalized mRNA cancer vaccines, that have demonstrated early promise in clinical development. In preclinical studies, vaccination with EVM16 stimulated a strong neoantigen-specific T cell response in different mouse models and showed significant tumor growth inhibition in the syngeneic B16F10 mouse melanoma model. Preclinical data also demonstrated that the combination of EVM16 and a PD-1 antibody has synergistic effect, which supports the clinical application of the combination of EVM16 with checkpoint inhibitors. In preclinical toxicity studies, repeated dosing with EVM16 was well tolerated and safe. Taken together, the preclinical immunogenicity, efficacy and safety studies demonstrate that EVM16 is safe and has potential to bring benefits to cancer patients.Everest has built end-to-end capabilities across its proprietary mRNA platform. Our R&D team is developing multiple mRNA-based therapeutic products, as well as next generation lipid nanoparticle (LNP) delivery systems to enhance cell-mediated immune response. Our mRNA manufacturing facility in Jiashan, Zhejiang Province in China is designed to comply with global cGMP standards and is able to produce at clinical- and commercial-scale. Everest owns full global intellectual property rights to its mRNA therapeutic programs.Reference:1.Globocan 2022: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdfAbout EVM16EVM16 is a novel personalized mRNA cancer vaccine independently developed by Everest Medicines Limited.. EVM16 contains neoantigens with high immunogenicity potential which are predicted by Everest-proprietary algorithm and uses an LNP delivery system to efficiently deliver mRNAs that express tumor neoantigens into the human body. After vaccination with EVM16, neoantigens-encoding mRNAs are delivered into cells to produce neoantigen peptides, which activate neoantigen-specific T cell immune responses to kill tumor cells, thereby inhibiting tumor growthAbout EVM16CX01 studyThe study is a FIH, dose escalation and expansion study to evaluate the safety, tolerability, immunogenicity, and initial efficacy of EVM16 injection as a single and in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors.,. The primary objectives are to evaluate the safety and tolerability of EVM16 monotherapy and EVM16 in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors, and to determine the recommended phase 2 dose (RP2D) of EVM16. The secondary objectives are to evaluate the immunogenicity of EVM16, and the initial efficacy of EVM16 in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders.For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2024 ACN Newswire via SeaPRwire.com.
新鴻基公司公佈2024中期業績
EQS 新聞 via SEAPRWire.com / 2024-08-22 / 12:00 UTC+8 審慎策略持續實現虧轉盈 （香港股份代號：86）（「新鴻基公司」或「公司」，連同其附屬公司「集團」）公布截至2024年6月30日止之中期業績大幅轉虧爲盈，反映了集團多元化業務模式的優勢，及公司在波動和不穩定的營商環境中，其戰略轉型所取得的進展。 新鴻基有限公司 財務摘要 截至下列日期止六個月 截至下列日期止年度 （百萬港元） 2024年 6月 2023年 6月 變動 2023年 12月 收入 1,915.8 1,968.3 -2.7% 3,916.6 除稅前溢利╱（虧損） 307.4 36.5 742.2% 76.6 本公司股東應佔溢利╱（虧損） 75.4 (287.5) N/A (471.4) 每股基本盈利╱（虧損）（港仙） 3.9 (14.7) N/A (24.1) 中期股息（港仙） 12.0 12.0 - 14.0^ 每股賬面值（港元） 10.7 11.0 -2.7% 10.8 ^ 第二次中期股息 儘管市場環境充滿挑戰，集團2024年上半年仍錄得收入1,915.8百萬港元(2023年上半年：1,968.3百萬港元)，主要包括來自信貸業務的利息收入1,650.2百萬港元。公司股東應佔溢利為75.4百萬港元，而去年同期的虧損為287.5百萬港元，實現顯著轉虧爲盈。 集團保持審慎態度，並積極管理其投資組合，繼續維持穩健的資產負債表和充足的流動性，以把握市場失序帶來的機遇。 董事會宣佈派發截至2024年6月30日止六個月之中期股息每股12港仙，維持與2023年上半年相同水平。 業務回顧 截至下例日期止六個月的除稅前貢獻 於下例日期的分項資產 （百萬港元） 2024 年 6月 2023 年 6月^ 變動 2024 年 6月 2023 年 12月^ 信貸業務 消費金融 400.3 553.8 -27.7% 17,598.0 18,062.9 按揭貸款 25.0 71.6 -65.1% 2,311.3 2,674.6 私募融資 -- (10.2) 不適用 -- -- 小計 425.3 615.2 -30.9% 19,909.3 20,737.5 投資管理 (358.4) (861.4) -58.4% 15,528.3 16,257.4 基金管理 1.3 16.3 -92.0% 21.6 24.9 集團管理及支援 239.2 266.4 -10.2% 4,046.5 3,849.7 總計 307.4 36.5 742.2% 39,505.7 40,869.5 ^ 經重列，因為私募融資中之定期貸款被重組至投資管理項下的特別機會 信貸業務維持穩健表現，於期內貢獻除稅前溢利425.3百萬港元，經營成本亦較去年同期減少，反映新鴻基公司一直致力提高營運效率。 儘管融資環境充滿挑戰，基金管理業務仍保持盈利趨勢。撇除2023年上半年出售East Point收入分成權的一次性影響，基金管理業務的除稅前貢獻與去年同期比較增長116.7%，助力集團轉型為領先的另類投資平台。 集團旗下基金及基金合作夥伴的總資產管理規模（「AUM」）錄得強勁增長，達到12億美元，創下該平台自2021年推出以來的最高紀錄。資產管理規模的增長受益於超過130百萬美元的淨現金流入和約100百萬美元的市場收益，幾乎所有策略均有良好貢獻。集團對該業務發展充滿信心，尤其是在與GAM Investments的戰略聯盟於2024年8月1日生效後，這聯盟擴展了集團的產品類別，並提升在大中華地區的客戶覆蓋範圍和服務能力。 集團的多家族辦公室平台「家族辦公室解決方案」持續取得進展，憑藉其獲得全球私募投資機會的優勢，不斷擴大客戶群。該業務為具有相似投資方式和期限的家族辦公室和高淨值人士提供定制的另類投資解決方案，在與客戶利益一致的基礎上創造回報。 投資管理部門亦錄得顯著改善，過去兩年投資管理的整體回報率繼續提高，期內獲得0.4%的正收益。投資管理在內部分配資本成本348.7百萬港元後，除稅前虧損大幅收窄58.4%至358.4百萬港元，比對2023年上半年虧損861.4百萬港元。這改善主要歸功於私募股權、對沖基金和企業持股的表現。特別機會和房地產則繼續帶來穩健回報。另類投資及房地產錄得172.2百萬港元未兌現收益，主要由於集團的對沖基金投資組合在積極調整至較保守的投資組合後，錄得強勁回報。 集團執行主席李成煌先生表示：「2024 年上半年我們一直保持審慎策略，並繼續回購公司的票據。雖然減息預期帶來了一些紓緩的作用，但 2024 年仍將會是複雜的一年。在全球經濟復甦仍不明朗，地緣政治緊張持續，美國總統大選帶來不確定性的背景下，我們對市場前景保持審慎樂觀，同時繼續減少市場風險敞口。我們亦對與 GAM Investments的新聯盟所帶來的潛在機遇感到興奮，並將繼續加強我們的投資及分銷能力。」 如欲了解更多2024年中期業績的詳細資料, 請參閱業績公告。 - 完 - 關於新鴻基有限公司 新鴻基有限公司(香港股份代號:86) (「新鴻基公司」/「本公司」，連同其附屬公司「本集團」) 是一家領先的香港金融機構，在另類投資和財富管理領域備受肯定。新鴻基公司成立於1969年，其多元化的投資組合，涵蓋公開市場、信貸和另類投資策略(其中包括房地產和私募股權)，締造長期經風險調整回報。憑藉其紮根亞洲的傳承，新鴻基公司支持和培育該地區優秀且具專業能力的新晉資產管理公司，賦能他們實現卓越表現。集團亦利用其長久以來建立的投資業務專長和豐富資源，透過其家族辦公室解決方案，為理念一致的合作伙伴和超高淨值投資者提供量身定制的投資解決方案。截至2024年6月30日，集團的資產總值約為395億港元。 如欲了解更多關於新鴻基公司的資訊，請瀏覽：www.shkco.com / 或在 LinkedIn 上關注我們。 媒體查詢，請聯絡： Hill and Knowlton 林貴珍 +852 9839 6552 冷書杰 +852 5443 4320 張夢瑩 +852 9794 5751 電郵：SHKCo@hkstrategies.com 2024-08-22 此財經新聞稿由EQS Group via SEAPRWire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php
樂普生物公佈2024年中期業績 ADC管線取得重大進展 核心産品營收大增一倍
香港, 2024年8月22日 - (亞太商訊 via SeaPRwire.com) —聚焦於腫瘤治療領域的創新型生物製藥公司──樂普生物科技股份有限公司(「樂普生物」或「公司」，股份代號：2157.HK) 公佈2024年中期業績。作為一家立足中國、面向全球的聚焦於腫瘤治療領域（尤其是靶向治療及免疫治療）的創新型生物製藥企業。樂普生物致力於通過先進的ADC技術開發平台開發創新型ADC，並旨在開發出更優化、更創新的藥物，更好地填補癌症患者的臨床需求缺口。公司致力於通過內部研發與戰略合作相結合的方式持續開發市場差異化管線，加強自主生產能力。目前，樂普生物已戰略性佈局了多個腫瘤產品管線。就臨床階段候選藥物而言，公司的產品中有一種臨床 / 商業化階段候選藥物；七種臨床階段候選藥物（包括一種透過合營企業共同開發的藥物）；及三種臨床階段的候選藥物的聯合療法。其中一種候選藥物已獲得兩種靶向適應症的上市批准，其他適應症臨床試驗正在進行中。商業化稳定再超億元 核心產品銷售較去年同期增加一倍於報告期內，公司在推進產品管線及業務營運方面均取得重大進展，其中核心產品普佑恆®（普特利單抗注射液）的銷售收入達人民幣94.8百萬元，較2023年同期增加一倍，為公司收益人民幣133.3百萬元之主要貢獻。ADC管線及其與癌症免疫的聯合療法亦取得多項重大進展。而於創新平台研發的候選藥物臨床前獲得良好數據。於2023年4月，普特利單抗已成功獲納入用於治療黑色素瘤和MSI-H/dMMR實體瘤的2023年CSCO及CSGO指南，表明臨床KOL的高度認可。公司積極發展與各種業務渠道合作夥伴的合作關係。截至2024年6月30日，已在26個省份的採購平台上完成了招標程序，并已通過各種銷售渠道覆蓋約78個城市，將進一步擴大銷售網絡。ADC管線及其與癌症免疫的聯合療法取得重大進展公司的ADC候選藥物包括MRG003、MRG002、MRG004A、MRG001、MRG006A及CMG901。ADC管線及其與癌症免疫的聯合療法在上半年取得了重大進展。- MRG003：目前已完成NPC IIb期註冊性臨床研究的患者入組，預期將於2024年下半年於中國申報NDA。於2024年7月，公司已就MRG003用於治療R/M NPC於美國獲FDA授予BTD。MRG003與普佑恆®（普特利單抗注射液）的聯合療法：公司正在進行MRG003與普特利單抗聯合治療實體瘤的I/II期試驗，並已完成I期試驗。公司已觀察到良好的初步數據，該等數據已在2024年ASCO年會上以口頭匯報形式呈現。公司目前正在進行II期試驗並已觀察到良好的數據，該等數據計劃於2024年ESMO亞洲年會上呈現。- MRG002：已於中國完成HER2高表達BC肝轉移II期關鍵臨床試驗的患者入組，並觀察到良好數據，預期將於2024年CSCO上呈現。同時，公司正在進行HER2陽性BC的III期臨床試驗。MRG002與普佑恆®（普特利單抗注射液）的聯合療法：公司正在進行MRG002與普特利單抗聯合治療HER2表達實體瘤患者的II期試驗，並已於UC患者中觀察到良好的初步數據，預期將在2024年ESMO大會上呈現。- MRG004A：公司目前正在美國及中國進行實體瘤I期臨床研究，並已在PC、TNBC及CC中觀察到良好數據。實體瘤的相關初步I期數據已在2024年ASCO年會上以口頭匯報形式呈現。於2024年3月，MRG004A已獲FDA授予FTD，用於治療經過過往批准的療法治療的復發性或難治性PC。公司正在擴展I期臨床試驗PC患者亞組，以進一步探索MRG004A用於PC的更多潛力。- MRG006A：公司已於2024年AACR年會上公佈良好的臨床前數據。於臨床前研究中，MRG006A在多種CDX模型及HCC PDX模型中展現出強大的劑量依賴性的對腫瘤的生長抑制作用。同時，MRG006A亦在探索性毒理學研究中表現出良好的耐受性。根據良好的臨床前表現，公司已於中國獲得IND批准，且目前正在進行I期臨床研究，而該研究已於2024年8月實現首例患者入組。臨床前：佈局創新平台和創新靶點公司持續致力於建立和開發新型技術平台。除臨床驗證的vc-MMAE平台外，亦已為ADC候選藥物開發多個創新的鏈接體－ 有效載荷平台，包括Hi-TOPi平台及其他早期階段的平台。於報告期內，公司的創新ADC平台及T細胞銜接器平台TOPAbody取得了重大進展。依託該等創新平台，已開發出兩款ADC候選藥物，分別為具有全球首創新藥潛力的MRG006A及具有全球同類最優潛力的MRG007，以及新一代T細胞激動性抗體CTM012。公司已觀察到良好的臨床前研究數據，並已於中國獲得MRG006A的IND批准。同時，亦正在高效推進MRG007及CTM012進入臨床研究階段。MRG006A及TOPAbody平台的臨床前數據已於2024年4月在AACR年會上呈現。未來展望展望2024年下半年，公司將繼續加快兩款主要ADC產品MRG003及MRG002的開發，邁向下一個里程碑。公司預期將於2024年下半年於中國就MRG003申報NDA，並將努力加快審批進程。公司亦將探索MRG004A及MRG006A等其他創新候選藥物的更多潛在臨床價值。同時，不斷探索管線內的聯合療法的潛在療效，以為更多患者帶來臨床效益。就創新分子而言，致力加強建設創新平台，並全力推進創新分子CTM012及MRG007進入臨床研究階段。2024年，公司將致力於深化市場營銷及商業化，並積極擴大在中國的市場足跡及產品知名度。這包括促進普佑恆®（普特利單抗注射液）的市場准入，繼續加快各級市場滲透，以進一步擴大市場份額。同時，公司將尋求通過各種方式提升品牌形象及市場對公司產品的認識。在國際方面，公司將加大在全球市場的拓展力度。由於ADC平台已獲跨國公司認可，預期公司的其他ADC產品將有更大的業務發展機會。日後，公司將堅持不懈地擴大國際網絡，並通過多項策略探索新的業務開發合作機會，以促進我們的發展及成功。 Copyright 2024 亞太商訊 via SeaPRwire.com.
賽晶科技公佈2024年度中期業績 錄得總收入人民幣6.56億元 同比增長43%
2024年度中期業績報告摘要（截至2024年6月30日止6個月）- 總收入為人民幣6.56億元，同比增加約43%；歸屬母公司淨利潤3,358萬元，同比扭虧為盈。- 配輸電業務方面，報告期內集團於該分領域的銷售收入達人民幣3.58億元，同比大幅增長105%。其中直流輸電業務同比增長177%，柔性輸電業務同比增長196%。- 研發方面，將在8月底正式發佈自研碳化矽（SiC MOSFET）晶片，電阻率低至13毫歐，達到了國際領先水準。香港, 2024年8月22日 - (亞太商訊 via SeaPRwire.com) — 賽晶科技集團有限公司（「賽晶科技」或「公司」，連同其附屬公司統稱「集團」；股份代號：0580.HK）披露截至2024年6月30日止半年度（「報告期內」）的業績公告。報告期內，公司總收入為人民幣6.56億元，較2023年同期增長43%；歸屬母公司淨利潤3,358萬元，同比扭虧為盈。其中，國內市場收入為人民幣6.17億元，較2023年同期增長40%；國外市場收入為人民幣3,871萬元，較2023年同期增長94%。 直流輸電業務高歌猛進，輸配電業務營收同比增長105% 隨著直流輸電專案數量與市場規模的迅猛擴張，公司依託在直流輸電領域穩固的行業領導地位，2024上半年輸配電業務營收達到3.58億元，同比增長105%。其中，在特高壓常規直流輸電板塊，公司圓滿交付了服務於“金上-湖北”、“哈密-重慶”、“寧夏-湖南”等國家級特高壓工程專案的關鍵設備訂單，推動該領域營收同比增長高達177%。在柔性輸電板塊，公司主要交付了用於德國BorWin6海上風電柔性直流輸電工程及國網四川成都供電公司66KV構網型直掛靜止無功發生器（SVG）的訂單，實現該領域營收同比增長196%。此外，公司自主研發的柔性直流輸電用直流支撐電容器，於2024年初通過國家級新技術產品鑒定，隨後在“國網四川成都供電公司66KV構網型直掛靜止無功發生器”及“華能玉環2號海上風電專案220千伏送出工程”等多個專案中實現批量供貨，並完成了100%的國產替代。有望在後續柔性輸電專案中，帶來新的業績增長空間。總體來看，常規直流輸電工程、柔性輸電工程的在建及儲備專案豐富。上半年“金上-湖北”等專案順利推進，同時“陝北-安徽”等多地儲備專案蓄勢待發，國外專案如“沙特中西和中南”等也有望開工。此外，“疆電送電川渝”等特高壓專案公佈，新型輸電技術如低頻、遠海風電直流等不斷湧現，拓寬市場空間。直流輸電行業快速增長，新技術需求旺盛，公司將憑藉領先地位，將持續推動業績高增長。功率半導體業務客戶數量大幅增長，晶片研發成果顯著上半年，公司自研功率半導體業務的市場推廣和客戶開拓工作依然取得了顯著成績。2024年上半年，儘管銷售收入受到一定影響，但客戶總數實現了同比104%、環比45%的大幅增長。其中，完成測試和供應商導入工作並進入批量供貨階段的客戶數量更是同比增長100%、環比增長125%。產能方面，上半年也實現了有序提升。公司已經啟動了第三條IGBT模組封裝測試生產線，及第一條碳化矽模組封測生產線的廠房內部建設和設備採購工作，有望在2024年底前完成生產調試前的全部準備工作。研發方面，上半年公司自研功率半導體領域取得了顯著成果。下半年將有一系列功率半導體晶片推出，進一步豐富了集團的晶片產品線，為公司在高端功率半導體市場的長遠發展奠定了堅實基礎：- 碳化矽（SiC MOSFET）晶片的研發，電阻率低至【13】毫歐，達到了國際領先水準，將在8月底正式發佈。- 採用第七代微溝槽技術的i23系列1200V / 300A IGBT晶片，即將研發完成。同時，採用i23系列晶片的1200V/800A、900A ED封裝IGBT模組也將陸續推出。- i20系列IGBT晶片產品線進一步擴展，即1200V / 200A、150A、100A，1700V / 150A、100A、75A等多款晶片研發進展順利，即將推出。- EP封裝IGBT模組，研發進展順利，即將推出。未來展望為加快構建新型電力系統，促進新能源高質量發展，推動大規模設備更新改造，國家電網公司公佈：今年全年電網投資將首次超過6000億元，比去年新增711億元。受益於此，特高壓常規和柔性直流輸電，及海上風電直流送出、構網型SVG、低頻輸電等柔性輸電領域將繼續呈現旺盛的市場需求，並有助於提升本集團的業績表現。公司繼續全力加強行銷開拓，促進自研功率半導體業務回升及其他各項業務繼續增長。- 完 -關於賽晶科技集團有限公司賽晶科技集團有限公司（簡稱“賽晶科技”），香港主機板上市，股票代碼0580.HK。賽晶科技是業內技術領先並深具影響力的電力電子器件供應商和系統集成商，是具備國際領先水準的創新研發型企業，在北京、浙江嘉善、江蘇無錫、湖北武漢，以及歐洲的瑞士和德國，擁有十餘家子公司。賽晶科技，是港股稀缺的涉及特高壓輸電、功率半導體、電動汽車、新能源電力行業的上市公司。賽晶科技業務涵蓋生產、傳輸、使用的新能源全產業鏈，涉及光伏、風電、直流輸電、智能電網、電動汽車、軌道交通、電氣化船舶、儲能及各類工業控制領域。特別是在特高壓輸電領域，賽晶科技的多款產品長期保持業內技術和市場的領先地位，已經累計參與超過40個特高壓、高壓輸電專案。賽晶科技擁有世界一流的功率半導體研發團隊，自研IGBT和SiC晶片及模組獲得了電動汽車、新能源發電、儲能和工業電控等領域客戶的廣泛認可。2023年，國內特高壓輸電專案密集開工，且未來多年的國內、國外市場需求潛力巨大。賽晶科技在特高壓領域的行業領先地位穩固、在手訂單充足、業務增長確定性極高。此外，2023年賽晶科技功率半導體業務的新產品頻出、產能釋放加速、市場開拓成果顯著，展現出光明而廣闊的發展前景。投資者及媒體查詢賽晶科技集團有限公司聯絡人︰吉慶電話：86-10-56301205 / 86-186-11693787電郵：jq@sunking-tech.com Copyright 2024 亞太商訊 via SeaPRwire.com.
美國經濟新增就業人數比最初報告少 818,000 人
(SeaPRwire) - 華盛頓——美國政府週三表示，從 2023 年 4 月到今年 3 月，美國經濟新增的職位比最初報告的少了 818,000 個。修正後的總數進一步證明了就業市場一直在穩步放緩，並可能加強聯準會很快開始降息的計劃。 勞工部估計，截至 3 月的 12 個月內，就業增長平均每月 174,000 個——比最初報告的每月 242,000 個下降了 68,000 個。週三發布的修正數據是初步的，最終數據將於明年 2 月發布。 降級估計隨之而來的是 7 月份的就業報告，該報告遠不及預期，導致許多經濟學家認為聯準會等待太久才開始降息以支持經濟。失業率連續第四個月上升，達到仍處於低位的 4.3%，雇主僅增加了 114,000 個就業機會。 聯準會在 2022 年和 2023 年 11 次加息以抑制通脹，通脹在兩年前突破了 40 年來的最高點。自那以後，同比通脹率已大幅下降——從 2022 年 6 月的 9.1% 降至 2.9%，為聯準會在 9 月中旬下次會議上開始降息鋪平了道路。 週三發布的招聘估計修正旨在更好地考慮到正在創建或倒閉的公司。 “這沒有挑戰我們仍然處於擴張時期的想法，但它確實表明我們應該預期每月的就業增長更加緩慢，並給聯準會降息帶來額外的壓力，”海軍聯邦信用合作社的經濟學家羅伯特·弗里克說。 在修正後的數據中，新的專業和商業服務業就業——包括管理人員和技術人員在內的一個廣泛類別——在截至 3 月的 12 個月內減少了 358,000 個。休閒和酒店業雇主——包括酒店和餐館——比最初報告的增加了 150,000 個。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
DreamFolks Expands Footprint to SEAsian Market
SINGAPORE, Aug 20, 2024 - (ACN Newswire via SeaPRwire.com) - DreamFolks, India's largest airport services aggregator, is proud to announce its strategic expansion into the Southeast Asian market. This milestone marks a significant step in DreamFolks' mission to redefine travel experiences on a global scale.Over the past 12 years, DreamFolks has revolutionized the airport services industry in India by offering a comprehensive suite of premium services through its proprietary technology platform. The company dominates the Indian domestic lounge access market for debit and credit card programs, boasting an impressive 90% market share and partnerships with most major banks and card networks in the country. The Company went public in September’22 with listings on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).DreamFolks' success stems from its cutting-edge in-house technology, which empowers banks and card networks to significantly enhance their card value propositions. This technology helps boost sales, drives loyalty and optimizes cost for these financial institutions. This tech-driven approach has been key to DreamFolks' success in India and will continue to fuel its expansion into other geographies.The company's global footprint now extends to over 3000 touchpoints across more than 100 countries and 500+ cities, serving millions of travellers annually. This extensive network positions DreamFolks uniquely to offer unparalleled service to its clients and their customers in the new markets.Building on its success in the Indian market, DreamFolks is now poised to bring its innovative service aggregation model to the Southeast Asian market with services like airport and railway lounges, e-SIM: travel SIM cards, meet and assist services, airport transfers, golf privileges and more to their customers.As part of this expansion, DreamFolks has established a regional office in Singapore, demonstrating its commitment to the market. The company has also bolstered its leadership team by on-boarding, Adib Kangda, Senior Vice President – International Markets, a seasoned professional with extensive knowledge of the local market dynamics.Liberatha Kallat, Chairperson and Managing Director of DreamFolks, commented on the expansion and said, "Our expansion into Southeast Asia marks a significant milestone in DreamFolks' journey. We're not just entering new markets; we're bringing our vision of seamless, technology-driven travel experiences to one of the world's most dynamic regions. This area represents immense opportunities for growth and innovation in the travel sector. With our proven track record in India, we're confident that our unique service aggregation model will resonate strongly with banks, card networks and enterprises across the region. By entering the Southeast Asian market, we will introduce market-first card innovations, and significantly save costs for our clients. Our focus is on delivering tangible benefits for our clients, ensuring they experience enhanced value and efficiency."This expansion is expected to benefit both clients and travellers in the region. By offering its advanced technology solutions, DreamFolks aims to help banks, card networks and enterprises optimise their offerings, enhance customer loyalty, and streamline operations. For travellers, this means access to a broader range of premium services and a more seamless travel experience. This expansion not only marks a new chapter in DreamFolks' journey but also promises to elevate the standards of travel services across the region.About DreamFolksDreamFolks is a leading travel & lifestyle services aggregator and provides an in-house technology platform that allows its clients such as Banks, Card Networks, Airlines, OTAs, and Enterprises to create custom offerings for their end consumers. DreamFolks today manages the lounge and other benefits for most of the top Banks in India and enjoys a market share of over 90% in the domestic lounge access market for India-issued debit and credit programs. The company went public in Sep ’22 with listings on both BSE and NSE and has a global footprint extending to 3,000+ touchpoints in 100+ countries, across the world.For more information, please visit our website (www.dreamfolks.com) or contact our media relations team.Contact Information: dreamfolks@adfactorspr.comNamrata Sharma – Namrata.sharma@adfactorspr.com Copyright 2024 ACN Newswire via SeaPRwire.com.